Patents Examined by Christine J. Saoud
  • Methods of treating an IGFBP-3R expressing cancer using anti-IGFBP-3R antibodies
    Patent number: 11179451
    Abstract: Insulin-like growth factor-binding protein 3 receptor (IGFBP-3R) agonists and methods of their use to treat diseases involving IGFBP-3 and IGFBP-3R are provided. The agonists may be antibodies or other molecules specific for binding to and activating IGFBP-3R. The agonists are used to treat e.g. cancer, metabolic syndrome and obstructive respiratory disorders. In addition, methods of diagnosing cancer and predicting the chance of recurrence, metastasis and/or survival by measuring the level of IGFBP-3R in tumor tissue are provided.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 23, 2021
    Assignee: Virginia Commonwealth University
    Inventors: Youngman Oh, Qing Cai
  • Nav1.9 target polypeptide, antibody and antibody fragment combined with same, and related pharmaceutical composition
    Patent number: 11174312
    Abstract: Provided is an antibody or a fragment thereof, which can be specifically bound to an S3-4 ring of a voltage sensor paddle of a domain III of voltage-gated sodium channel Nav1.9 ? sub-unit, and is able to inactivate a voltage sensor valve to keep sodium ions from entering nerve cells normally. Also provided is an epitope polypeptide specifically bound to the antibody or the fragment thereof, a pharmaceutical composition comprising the antibody or the fragment thereof, and a use of the antibody or the fragment thereof in preparing a drug for treating and diseases related to pains.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 16, 2021
    Assignee: POPULAS BIOPHARMACEUTICAL (WUHAN) LIMITED
    Inventor: Daichang Yang
  • Method of treating Rett Syndrome (RTT) with ghrelin
    Patent number: 11154592
    Abstract: A method of treating Rett Syndrome (RTT) comprising administering ghrelin to a subject in need thereof.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: October 26, 2021
    Assignee: KURUME UNIVERSITY
    Inventors: Toyojiro Matsuishi, Masayasu Kojima, Kotaro Yuge, Munetsugu Hara, Yushiro Yamashita
  • Anti-TREM-1 antibodies and uses thereof
    Patent number: 11155618
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 26, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
  • vNAR antibody which binds VEGF for use in dogs or cats
    Patent number: 11155612
    Abstract: The present invention relates to a novel vNAR protein of SEQ ID NO:1 capable of inhibiting the activity of VEGF in carnivorous mammals of the Canis and Felis genera, thereby inhibiting solid tumors growth of both genres.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 26, 2021
    Inventors: Alexei Fedorovish Licea Navarro, Dalia Vanessa Millán Gómez, Liliana Noemi Sánchez Campos, Carolina Elosua Portugal, Jorge Fernando Paniagua Solís, Salvador Dueñas Espinoza
  • Dual PDGF/VEGF antagonists
    Patent number: 11155610
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: October 26, 2021
    Assignee: KODIAK SCIENCES INC.
    Inventors: Daniel Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • Patient-specific biomarkers of invasion in inflammatory bowel disease
    Patent number: 11150237
    Abstract: The present invention provides methods of detecting increased carcinoembryonic antigen-related cell adhesion molecule (CEACAM) protein expression in a biological sample from a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene. The invention also provides methods of treating or preventing inflammatory bowel disease (IBD) in a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene.
    Type: Grant
    Filed: April 1, 2019
    Date of Patent: October 19, 2021
    Assignee: The Regents of the University of California
    Inventor: Declan McCole
  • Long-acting FGF21 fusion proteins and pharmaceutical composition comprising same
    Patent number: 11142557
    Abstract: The present invention provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. The fusion protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition comprising the fusion protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 12, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Jun Hwan Kim, Seyoung Lim, Minji Seo, Hyun Ho Choi, Dohoon Kim, Mi Kyeong Ju, Ju-Young Park, Byung Hyun Choi, Jun Kyung Lee, Jong Gyun Kim, Su Youn Nam
  • Methods of screening compounds useful for treatment of a liver disease
    Patent number: 11141423
    Abstract: Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: October 12, 2021
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Lakshmi A. Devi, Raphael Rozenfeld
  • Antibodies and antibody fragments for binding to NAV1.9 polypeptides and methods for using same to treat pain-related disease
    Patent number: 11136382
    Abstract: The present invention provides an antibody or antibody fragment thereof for a targeted cytomembrane voltage-gated sodium channel ? subunit Nav1.9. The specific binding target is a S3-4 ring of a voltage sensor paddle of a domain II of the voltage-gated sodium channel ? subunit. The antibody or antibody fragment thereof is able to inactivate a voltage sensor valve, to make sodium ions unable to enter nerve cells normally, thereby achieving the effect of treating and relieving pains.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: October 5, 2021
    Assignee: POPULAS BIOPHARMACEUTICAL (WUHAN) LIMITED
    Inventor: Daichang Yang
  • Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same
    Patent number: 11136364
    Abstract: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: October 5, 2021
    Assignee: YUHAN CORPORATION
    Inventors: Jun Hwan Kim, Seyoung Lim, Minji Seo, Hyun Ho Choi, Dohoon Kim, Mi Kyeong Ju, Ju-Young Park, Seul Gi Kim, Sangmyoun Lim, Jong Gyun Kim, Su Youn Nam
  • Aflibercept formulations and uses thereof
    Patent number: 11135266
    Abstract: Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: October 5, 2021
    Assignee: Just-Evotec Biologics, Inc.
    Inventors: Bruce A. Kerwin, Julee A. Floyd, Alison J. Gillespie, Christine C. Siska
  • Nucleic acids encoding FGF21-Fc fusion proteins
    Patent number: 11129874
    Abstract: The invention relates to nucleic acids encoding fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are vectors and host cells comprising the same and methods of producing the fusion proteins.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 28, 2021
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosis
    Patent number: 11103554
    Abstract: The invention relates to methods of using variants of fibroblast growth factor 19 (FGF19) for reducing bile acid synthesis in a subject having cirrhosis.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: August 31, 2021
    Assignee: NGM BIOPHARMACEUTICALS, INC.
    Inventors: Lei Ling, Jian Luo
  • Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides
    Patent number: 11103558
    Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: August 31, 2021
    Assignee: Duke University
    Inventor: Ashutosh Chilkoti
  • High concentration VEGF receptor fusion protein containing formulations
    Patent number: 11103552
    Abstract: The present invention provides ophthalmic formulations having high concentrations of vascular endothelial growth factor (VEGF) receptor fusion protein and high stability during storage. Methods for treating angiogenic eye disorders using the high concentration formulations are also provided.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: August 31, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kenneth S. Graham, Saurabh Wadhwa
  • Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
    Patent number: 11097005
    Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: August 24, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
  • Treatment of Hodgkin lymphoma using an anti-PD-1 antibody
    Patent number: 11083790
    Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising nivolumab, a PD-1-blocking antibody, that inhibits tumor immune evasion in patients with relapsed or refractory Hodgkin's lymphoma.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: August 10, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventor: Benedetto Farsaci
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11084865
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
    Patent number: 11072640
    Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 27, 2021
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu